Sale of Future Revenue - Narrative (Details) - USD ($) $ in Thousands		2 Months Ended	3 Months Ended	12 Months Ended		26 Months Ended	50 Months Ended
	Nov. 03, 2020	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2024
Disaggregation of Revenue [Line Items]
Payments of financing costs				$ 0	$ 4,643
Revenues				57,561	50,583
License Agreement with Sunovion Pharmaceuticals, Inc.
Disaggregation of Revenue [Line Items]
Minimum royalty receivable			$ 1,000	1			$ 1
Monetization Agreement
Disaggregation of Revenue [Line Items]
Payments of financing costs				2,909
Effective annual interest rate	24.90%
Monetization Agreement | Marathon Pangolin Royalty LLC
Disaggregation of Revenue [Line Items]
Proceeds from sale of future revenues, net	$ 40,000	$ 10,000				$ 50,000	$ 50,000
Proceeds from debt, contingent on additional milestones	75,000
Royalty
Disaggregation of Revenue [Line Items]
Revenues				$ 1,008	$ 989
Royalty | License Agreement with Sunovion Pharmaceuticals, Inc.
Disaggregation of Revenue [Line Items]
Revenues			$ 8,000
Maximum | Marathon Pangolin Royalty LLC
Disaggregation of Revenue [Line Items]
Proceeds from sale of future revenues, net	$ 125,000